RIPK1 targeting protects against obesity and atherosclerosis.

Unhealthy lifestyles and dietary habits often lead to diet-associated inflammatory diseases such as obesity and atherosclerosis. Recent studies have provided novel insight into the role of RIPK1 in inflammation and metabolism. RIPK1 silencing can reduce diet-induced obesity, nonalcoholic fatty liver disease (NAFLD), and atherosclerosis by reducing inflammation, lipid synthesis, and inflammasome activation. Targeting RIPK1 may therefore attenuate chronic metabolic disease and would likely be therapeutic.